Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

• Status: Completed
• Trial end date: 2016-11-03
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk Non-Hodgkin's Lymphoma (NHL).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: GlaxoSmithKline
• Treatments: Antibodies; Antibodies, Monoclonal; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Etoposide phosphate; Iodine-131 anti-B1 antibody; Liposomal doxorubicin; Rituximab

Criteria

Inclusion Criteria:

• Untreated, biopsy proven B-cell non-Hodgkin's lymphoma

• Age >/= 18 years

• No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for one year. The patient cannot have been exposed to chemotherapy to treat any of these diseases for at least 3 years prior to study entry.

• Meet staging studies and laboratory tests prior to induction, consolidation and radioimmunotherapy.

Exclusion Criteria:

• Significant medical and/or psychiatric illness which may compromise planned treatment;

• Pregnant or lactating;

• HIV-infection.

• Patients with follicular lymphoma grade 1, 2 or 3A are not eligible for this trial.